BioSpace News Archive

The rising threat of antimicrobial resistance on the back of antibiotics overuse and the expanding demand for animal-derived products will set the stage of growth for the veterinary antimicrobial susceptibility testing market during the forecast period of 2021-2031.

Developments in the market for pharmacy inventory management software solutions and cabinets rides on the back of the rising adoption of automation solutions across the stages of healthcare delivery, including in pharmacy.

Amsterdam, the Netherlands – Royal Philips, a global leader in health technology, announced the launch of its next-generation digital pathology solution, moving digital pathology into the heart of enterprise-wide healthcare informatics.

Silence Therapeutics plc and Hansoh Pharmaceutical Group Company Limited announced a collaboration to develop siRNAs for three undisclosed targets leveraging Silence’s proprietary mRNAi GOLD™ platform.

Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment.

Pfizer Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the 100 mg and 200 mg doses of abrocitinib, an oral, once-daily, Janus kinase 1 inhibitor, for marketing authorization to treat moderate to severe atopic dermatitis in adults who are candidates for systemic therapy.

Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have growth failure due to inadequate secretion of endogenous growth hormone (GH).

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the presentation of data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021, being held virtually November 12 – 15.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health outcomes research abstract have been accepted for oral and poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®.

AbbVie (NYSE: ABBV) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of risankizumab (SKYRIZI®, 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter) alone or in combination with methotrexate (MTX).